Clinical trials
Pembrolizumab clinical trials
Below are recruiting pembrolizumab clinical trials, each written for real people, not researchers. We’re tracking 611 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06077760RecruitingPhase 3
Personalized cancer vaccine plus Keytruda for lung cancer after surgery
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
Anchorage, AlaskaAges 18 years+ - NCT06102395RecruitingPhase 3
Pembrolizumab plus chemo before surgery for advanced head and neck cancer
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06170788RecruitingPhase 3
New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Phoenix, ArizonaAges 18 years+ - NCT06389422RecruitingPhase 2
Radiation plus Keytruda for liver cancer with vein clots
This trial tests a combination of moderate-dose radiation therapy and the immunotherapy drug pembrolizumab (Keytruda) for liver cancer that has spread into the main veins of the liver. It aims to see if this combination can shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–90 - NCT06502743RecruitingPhase 2
Study of chemotherapy and pembrolizumab with or without nesuparib for endometrial cancer
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Kyeonggi-doAges 19 years+ - NCT06525220RecruitingPhase 3
New drug combo vs. standard for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
Mobile, AlabamaAges 18 years+ - NCT06624644RecruitingPhase 2/Phase 3
LNS8801 with or without pembrolizumab for advanced melanoma
This trial tests a new drug called LNS8801, alone or with pembrolizumab, for people with advanced melanoma that has stopped responding to prior treatments, especially anti-PD-1 therapy.
Newport Beach, CaliforniaAges 18 years+ - NCT06788912RecruitingPhase 2
Study of pembrolizumab plus other drugs before lung cancer surgery
This trial is testing a new combination of drugs (including pembrolizumab) as a treatment before surgery for people with a certain type of lung cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Daphne, AlabamaAges 18 years+ - NCT07027124RecruitingPhase 2
High-risk prostate cancer treatment before and after surgery
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
New York, New YorkAges 18 years+ - NCT07261683RecruitingPhase 2
Combination therapy for recurrent ovarian cancer
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07283731RecruitingPhase 2
Testing zanzalintinib plus pembrolizumab for certain sarcomas
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
Houston, TexasAges 18 years+ - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Birmingham, AlabamaAges 18 years+ - NCT07660094RecruitingPhase 3
New treatment for advanced lung cancer that has stopped responding to immunotherapy
This trial tests a new investigational medicine (aglatimagene besadenovec) plus pembrolizumab against standard chemotherapy (docetaxel) for people with stage IV non-squamous lung cancer that has stopped responding to pembrolizumab. The new treatment is given as a tumor injection (like a biopsy) along with a pill (prodrug) and an infusion of pembrolizumab. The goal is to see if it can re-engage the immune system to fight the cancer.
New York, New YorkAges 18 years+ - NCT07475806RecruitingPhase 2
Bladder-sparing drug combo for muscle-invasive bladder cancer
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
Little Rock, ArkansasAges 18 years+ - NCT06989112RecruitingPhase 3
First-line treatment for advanced or recurrent endometrial cancer
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
Tucson, ArizonaAges 18 years+ - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Fayetteville, ArkansasAges 18 years+ - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Phoenix, ArizonaAges 18 years+ - NCT05901285RecruitingPhase 1
Vaccine injected into tumors plus immunotherapy for advanced cancers
This Phase 1 trial tests a cancer vaccine (VAX014) injected directly into a tumor, given alone at first and then with an immune checkpoint medicine (nivolumab or pembrolizumab). It aims to see how well this approach is tolerated and may help shrink advanced solid tumors after other treatments stopped working.
Tucson, ArizonaAges 18 years+ - NCT07361510RecruitingPhase 3
Pumitamig vs Keytruda for advanced lung cancer with high PD-L1
This trial compares an experimental drug called Pumitamig with the approved immunotherapy drug Pembrolizumab (Keytruda) as the first treatment for advanced lung cancer that has high PD-L1 levels. The goal is to see which drug works better and has fewer side effects.
Daphne, AlabamaAges 18 years+ - NCT07198074RecruitingPhase 3
Testing Avastin added to chemo plus Keytruda for certain endometrial cancer
This study tests adding Avastin (bevacizumab) to the standard combination of chemotherapy (carboplatin and paclitaxel) plus immunotherapy (Keytruda) for advanced or recurrent endometrial cancer with a specific genetic makeup (pMMR and TP53 mutation). The goal is to see if adding Avastin helps shrink tumors or slow their growth.
Birmingham, AlabamaAges 18 years+ - NCT07513376RecruitingPhase 3
Adjuvant vaccine plus immunotherapy for high-risk early lung cancer
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
New Haven, ConnecticutAges 18 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Gilbert, ArizonaAges 18 years+ - NCT06809140RecruitingPhase 2
Bladder-sparing treatment for muscle-invasive bladder cancer
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
Duarte, CaliforniaAges 18 years+ - NCT07187778RecruitingPhase 2
Comparing two drugs before kidney cancer surgery
This trial tests two different medicines (belzutifan and pembrolizumab), given alone or together, before surgery to remove kidney cancer. The goal is to see if these treatments shrink the tumor and improve outcomes for people with high-risk kidney cancer.
Houston, TexasAges 18 years+
Hear when a new Pembrolizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pembrolizumab?
- Yes. Clin2 currently lists 611 recruiting pembrolizumab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pembrolizumab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pembrolizumab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.